TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01779206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT01725282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine extended release (XR)
Description: Extended release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine extended release (XR)
Description: Extended release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: quetiapine extended release (XR)
Description: Extended release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablets
Study: NCT04544111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube
Study: NCT05315219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Thyroidectomy Bilateral Areola Approach
Description: The endoscopic thyroidectomy achieves better cosmetic effects than open thyroidectomy, and is one of the most widely applied approach in China, meanwhile its safety and effectiveness has been broadly discussed since being introduced.
Study: NCT03717259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open nephrectomy
Description: The surgical technique for open nephrectomy consists of placing the donor in the lateral decubitus position and making an incision with or without rib resection that allows retroperitoneal access.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-assisted laparoscopic nephrectomy
Description: The hand-assisted technique begins with the incision for the introduction port of the hand, the renal artery and vein are divided using endoscopic staples and the graft is manually removed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic nephrectomy
Description: In the pure laparoscopic technique the patient is placed in the same position of lateral decubitus and after introducing the trocars in the abdomen, the colon is mobilized and the renal capsule is divided, the kidney is removed after performing the cut of the renal artery and vein through a suprapubic incision.
Study: NCT03020095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravidasvir
Description: Ravidasvir 200mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danoprevir
Description: Danoprevir 100mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir 100mg tablet administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin(RBV)1000/1200 mg/day (bodyweight\<75/≥75 kg)administered orally
Study: NCT04179461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emollient cream
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: Nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma Controller Medication
Description: Study participants asthma controller medication may be increased based off of their asthma control and the recommendation of the personalized plan.
Study: NCT03100838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Reference Drug (Brand)
Study: NCT03125642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: BEAM \& CBV: 300 mg/m\^2 IV over over 2 hours on Day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AraC
Description: BEAM: 100 mg/m\^2 IV over 1 hour BID on Days -5, -4, -3, -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: BEAM: 140 mg/m\^2 IV over 20 minutes on Day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation
Description: All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation
Description: All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is \>2500 x 10\^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm\^3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: CBV: 1.5 gm/M\^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 \| CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6
Study: NCT03401853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03125642

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
Study: NCT02556086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Study: NCT04172831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study: NCT04210973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anyu Peibo
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Study: NCT03662022

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.

Intervention type: DRUG
Group type: OTHER
Intervention: Rifampicin
Description: Rifampicin will be given in the same way to arms 2, 3 and 4 (weight dependent). Only the strategy of whom to offer PEP differs between the arms.
Study: NCT04544111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg twice daily (OR at dose the patient previously tolerated)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400mg IV every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: 400mg IV every 4 weeks
Study: NCT04581629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encaleret
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encaleret
Description: Tablets administered orally
Study: NCT03401853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study: NCT01178255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: homeopathic q-potencies
Description: individualised homeopathic medicines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: homeopathic q-potencies
Description: individualised homeopathic medicines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history taking type I
Description: one special homeopathic technique for case history taking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history taking type I
Description: one special homeopathic technique for case history taking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history type II
Description: another type of homeopathic case history taking

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: homeopathic case history type II
Description: another type of homeopathic case history taking
Study: NCT04483687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Match Filgotinib
Description: Tablets administered orally once daily
Study: NCT00531674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified milk-based beverage
Description: Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: tablets
Description: Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified milk-based pap
Description: Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles
Description: Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Syrup
Description: Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
Study: NCT01879527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride hydrochlorothiazide
Description: Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: containing placebo
Study: NCT02812303

Intervention type: OTHER
Intervention: Centralized support for population health management activities
Study: NCT02278471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Study: NCT04997590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood mononuclear cells
Description: injection of CB-MNCs (cell count 1×108 cells/time) was performed once every 2 week for a total of 3 times.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Staphylococcal Enterotoxin C
Description: injection of staphylococcal enterotoxin C was performed once every 2 week for a total of 3 times.
Study: NCT00640835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone Film Strip
Description: Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone Film Strip
Description: Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
Study: NCT03100838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Reference Drug (Brand)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Test Drug (Generic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 60 MG Extended Release Oral Tablet
Description: Test Drug (Generic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole/sodium bicarbonate
Description: Proton Pump Inhibitor/Antacid for drug-drug interaction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole/sodium bicarbonate
Description: Proton Pump Inhibitor/Antacid for drug-drug interaction
Study: NCT01344031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03100838

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology
Study: NCT02426450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: RFA:~RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil/Leucovorin
Description: 4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.~Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.~Repeated every 2 weeks
Study: NCT00889486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03993145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based lifestyle intervention
Description: Lifestyle intervention program including educational modules on diet and physical activity with visual and audio. Phone conversation with the clinical dietician at week 1, week 3, week 6, week 12 and month 6 (completion of the study).
Study: NCT01490190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)
Description: Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
Study: NCT02757703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatostatin
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Terlipressin
Description: A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
Study: NCT01337427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIIB017
Description: BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
Study: NCT03431558

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bLF (Bovine lactoferrin)
Description: BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: bLF (Bovine lactoferrin)
Description: BLF administration in two different strengths (150 \& 300mg) will be given on the third day of life with a single daily dose mixed with milk for 1 month.
Study: NCT03100838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartPill (TM)
Description: Gastric pH measurement using SmartPill (TM) Technology